News & Events

Renewal of Agreement with Merck

Physiomics plc (Oxford, UK) is pleased to announce that, following a successful collaboration this year and pursuant to the Master Services Agreement signed with Merck,…

Results of AGM

The Company held its Annual General Meeting at its offices in Oxford on 20th November 2018 and is pleased to announce that all resolutions put to…

Physiomics to host stand at EORTC Dublin

Physiomics plc is pleased to announce that it will be attending the 30th EORTC-NCI-AACR SYMPOSIUM in Dublin 13-16 November 2018. The European Organisation for…

Dispatch of Annual Report and Shareholder Circular

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today posted to shareholders its Annual Report…

Dr Jim Millen interviewed by Proactive Investors

Dr Jim Millen, CEO of Physiomics, talks to Proactive Investors’ Andrew Scott about recent successes and the company’s future direction. Please click here to…

Final Results for the year ended 30 June 2018

Chairman and Chief Executive Officer’s Statement Introduction We are very pleased to report on a year when we generated the highest total income in the…

Contract award

Physiomics is delighted to announce that it has been awarded a contract by a new European biotech client.  The value of the contract is £55k…

Physiomics expands technical team

Physiomics is pleased to announce that Dr Claire Villette has joined its technical team as a Biosimulation scientist. Click here to read in full.

Trading update

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm…

Dr Orrell to present at ISF conference

Physiomics consultant and senior advisor, Dr David Orrell, will give one of the keynote speeches at the 38th International Symposium on Forecasting, Colorado USA on 17th…